{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T11:26:41Z","timestamp":1764761201320,"version":"3.46.0"},"reference-count":39,"publisher":"Becaris Publishing Limited","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Comp. Eff. Res."],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:p>\n                    <jats:bold>Aim:<\/jats:bold>\n                    We compared the effects of nefecon, an oral targeted-release budesonide formulation, and sparsentan, an oral, dual endothelin-angiotensin receptor antagonist, on estimated glomerular filtration rate (eGFR) in patients with immunoglobulin A nephropathy, a leading cause of chronic kidney disease.\n                    <jats:bold>Materials &amp; methods:<\/jats:bold>\n                    We conducted an anchored matching-adjusted indirect comparison (MAIC) using patient-level data from NefIgArd (\n                    <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03643965\">NCT03643965<\/jats:ext-link>\n                    ; n\u00a0=\u00a0364), a randomized (1:1) trial of nefecon plus optimized renin\u2013angiotensin system inhibitor (RASi) therapy versus placebo plus RASi; and aggregate data from PROTECT (\n                    <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03762850\">NCT03762850<\/jats:ext-link>\n                    ; n\u00a0=\u00a0404), a randomized (1:1) trial of sparsentan versus irbesartan, an angiotensin receptor blocker. Mean absolute eGFR change and mean relative urine protein-to-creatinine and urine albumin-to-creatinine ratio changes from baseline at 9, 12 and 24\u00a0months (NefIgArd) or 36, 48 and 106\u00a0weeks (PROTECT) were analyzed using a mixed-effects model for repeated measures. A composite outcome (time to confirmed 40% eGFR reduction, end-stage kidney disease or all-cause mortality) was also included. An unanchored MAIC and network meta-analysis were used as sensitivity analyses.\n                    <jats:bold>Results:<\/jats:bold>\n                    The matching process reduced the effective sample for the NefIgArd trial from 364 to 208. Absolute eGFR change significantly favored nefecon over sparsentan at 9\u00a0months (mean difference, ml\/min\/1.73\u00a0m\n                    <jats:sup>2<\/jats:sup>\n                    [95% credible interval]: 5.7 [3.1\u20138.2]), 12\u00a0months (3.5 [1.0\u20136.0]) and 24\u00a0months (3.3 [0.0\u20136.5]). Differences in other outcomes were generally not statistically significant. Sensitivity analysis results were consistent with the main findings.\n                    <jats:bold>Conclusion:<\/jats:bold>\n                    In patients with immunoglobulin A nephropathy, nefecon plus optimized RASi may preserve kidney function to a greater extent than sparsentan.\n                  <\/jats:p>","DOI":"10.57264\/cer-2025-0045","type":"journal-article","created":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T12:16:52Z","timestamp":1763641012000},"source":"Crossref","is-referenced-by-count":0,"title":["Matching-adjusted indirect comparison of kidney function in patients with immunoglobulin A nephropathy treated with nefecon or sparsentan"],"prefix":"10.57264","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4136-1550","authenticated-orcid":false,"given":"Christopher","family":"Ngai","sequence":"first","affiliation":[{"name":"Calliditas Therapeutics, New York, NY 10017, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mit","family":"Patel","sequence":"additional","affiliation":[{"name":"Calliditas Therapeutics, New York, NY 10017, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agnieszka","family":"Kopiec","sequence":"additional","affiliation":[{"name":"Certara, Krak\u00f3w, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuai","family":"Fu","sequence":"additional","affiliation":[{"name":"Huaiyin Institute of Technology, Huai'an, Jiangsu Province, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-5656-5025","authenticated-orcid":false,"given":"Noemi","family":"Hummel","sequence":"additional","affiliation":[{"name":"Certara GmbH, L\u00f6rrach, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"36897","reference":[{"issue":"1","key":"e_1_3_10_3_2","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41581-024-00885-3","article-title":"The pathogenesis of IgA nephropathy and implications for treatment","volume":"21","author":"Cheung CK","year":"2025","unstructured":"Cheung CK, Alexander S, Reich HN The pathogenesis of IgA nephropathy and implications for treatment. Nat. Rev. Nephrol. 21(1), 9\u201323 (2025).","journal-title":"Nat. Rev. Nephrol."},{"issue":"6","key":"e_1_3_10_4_2","doi-asserted-by":"crossref","first-page":"727","DOI":"10.2215\/CJN.0000000000000135","article-title":"Long-term outcomes in IgA nephropathy","volume":"18","author":"Pitcher D","year":"2023","unstructured":"Pitcher D, Braddon F, Hendry B Long-term outcomes in IgA nephropathy. Clin. J. Am. Soc. Nephrol. 18(6), 727\u2013738 (2023).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"issue":"10","key":"e_1_3_10_5_2","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1016\/j.ekir.2020.08.009","article-title":"Why target the gut to treat IgA nephropathy?","volume":"5","author":"Barratt J","year":"2020","unstructured":"Barratt J, Rovin BH, Cattran D Why target the gut to treat IgA nephropathy? Kidney Int. Rep. 5(10), 1620\u20131624 (2020).","journal-title":"Kidney Int. Rep."},{"issue":"4","key":"e_1_3_10_6_2","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.kint.2021.05.021","article-title":"KDIGO 2021 clinical practice guideline for the management of glomerular diseases","volume":"100","author":"Kidney Disease: Improving Global Outcomes Glomerular Diseases Work Group","year":"2021","unstructured":"Kidney Disease: Improving Global Outcomes Glomerular Diseases Work Group. KDIGO 2021 clinical practice guideline for the management of glomerular diseases. Kidney Int. 100(Suppl. 4), S1\u2013S276 (2021).","journal-title":"Kidney Int."},{"key":"e_1_3_10_7_2","doi-asserted-by":"crossref","first-page":"3415","DOI":"10.2147\/DDDT.S383138","article-title":"Insights on Nefecon\u00ae, a targeted-release formulation of budesonide and its selective immunomodulatory effects in patients with IgA nephropathy","volume":"18","author":"Barratt J","year":"2024","unstructured":"Barratt J, Kristensen J, Pedersen C, Jerling M. Insights on Nefecon\u00ae, a targeted-release formulation of budesonide and its selective immunomodulatory effects in patients with IgA nephropathy. Drug Des. Devel. Ther. 18, 3415\u20133428 (2024).","journal-title":"Drug Des. Devel. Ther."},{"key":"e_1_3_10_8_2","unstructured":"PR Newswire. FDA grants Calliditas Therapeutics accelerated approval of TARPEYO\u2122 (budesonide) to reduce proteinuria in IgA nephropathy. (Accessed: 19 September 2025). https:\/\/www.prnewswire.com\/news-releases\/fda-grants-calliditas-therapeutics-accelerated-approval-of-tarpeyo-budesonide-to-reduce-proteinuria-in-iga-nephropathy-301445918.html"},{"key":"e_1_3_10_9_2","unstructured":"PR Newswire. Everest Medicines' partner Calliditas Therapeutics announces Nefecon\u00ae the only FDA-approved treatment for IgA nephropathy to significantly slow kidney function decline. (Accessed: 19 September 2025). https:\/\/www.prnewswire.com\/news-releases\/everest-medicines-partner-calliditas-therapeutics-announces-nefecon-the-only-fda-approved-treatment-for-iga-nephropathy-to-significantly-slow-kidney-function-decline-302020586.html"},{"key":"e_1_3_10_10_2","unstructured":"Calliditas Therapeutics AB. Tarpeyo\u00ae (targeted release formulation budesonide) US Food and Drug Administration. US Prescribing Information. (2024). https:\/\/www.tarpeyo.com\/prescribinginformation.pdf"},{"issue":"10405","key":"e_1_3_10_11_2","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/S0140-6736(23)01554-4","article-title":"Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase III trial","volume":"402","author":"Lafayette R","year":"2023","unstructured":"Lafayette R, Kristensen J, Stone A Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase III trial. Lancet 402(10405), 859\u2013870 (2023).","journal-title":"Lancet"},{"key":"e_1_3_10_12_2","unstructured":"STADA Arzneimittel AG. Kinpeygo (budesonide) European Summary of Product Characteristics. (2023). https:\/\/www.ema.europa.eu\/documents\/product-information\/kinpeygo-epar-product-information_en.pdf"},{"key":"e_1_3_10_13_2","unstructured":"Zhou W. Nefecon approved for use in China. (Accessed: 19 September 2025). https:\/\/global.chinadaily.com.cn\/a\/202311\/28\/WS65655deda31090682a5f0630.html#"},{"issue":"11","key":"e_1_3_10_14_2","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1042\/CS20240249","article-title":"Mechanism of protective actions of sparsentan in the kidney: lessons from studies in models of chronic kidney disease","volume":"138","author":"Kohan DE","year":"2024","unstructured":"Kohan DE, Bedard PW, Jenkinson C, Hendry B, Komers R. Mechanism of protective actions of sparsentan in the kidney: lessons from studies in models of chronic kidney disease. Clin. Sci. (Lond.) 138(11), 645\u2013662 (2024).","journal-title":"Clin. Sci. (Lond.)"},{"key":"e_1_3_10_15_2","unstructured":"Travere Therapeutics Inc. Travere therapeutics announces FDA accelerated approval of FILSPARI\u2122 (sparsentan) the first and only non-immunosuppressive therapy for the reduction of proteinuria in IgAN nephropathy. (Accessed: 19 September 2025). https:\/\/ir.travere.com\/news-releases\/news-release-details\/travere-therapeutics-announces-fda-accelerated-approval"},{"key":"e_1_3_10_16_2","unstructured":"Travere Therapeutics Inc. Travere Therapeutics announces full FDA approval of FILSPARI\u00ae (sparsentan) the only non-immunosuppressive treatment that significantly slows kidney function decline in IgA nephropathy. (Accessed: 19 September 2025). https:\/\/ir.travere.com\/news-releases\/news-release-details\/travere-therapeutics-announces-full-fda-approval-filsparir"},{"issue":"10417","key":"e_1_3_10_17_2","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1016\/S0140-6736(23)02302-4","article-title":"Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase III trial","volume":"402","author":"Rovin BH","year":"2023","unstructured":"Rovin BH, Barratt J, Heerspink HJL Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase III trial. Lancet 402(10417), 2077\u20132090 (2023).","journal-title":"Lancet"},{"key":"e_1_3_10_18_2","unstructured":"Travere Therapeutics Inc. Travere Therapeutics and CSL Vifor Announce Standard EU Approval of FILSPARI\u00ae (sparsentan) for IgA Nephropathy. (Accessed: 19 September 2025). https:\/\/ir.travere.com\/press-releases\/news-details\/2025\/Travere-Therapeutics-and-CSL-Vifor-Announce-Standard-EU-Approval-of-FILSPARI-sparsentan-for-IgA-Nephropathy\/default.aspx"},{"key":"e_1_3_10_19_2","unstructured":"Travere Therapeutics Inc. Travere Therapeutics and CSL Vifor announce Swissmedic approval of FILSPARI\u00ae (sparsentan) for the treatment of IgA nephropathy. (Accessed: 19 September 2025). https:\/\/ir.travere.com\/news-releases\/news-release-details\/travere-therapeutics-and-csl-vifor-announce-swissmedic-approval"},{"key":"e_1_3_10_20_2","doi-asserted-by":"publisher","DOI":"10.3390\/jmahp12020006"},{"issue":"7","key":"e_1_3_10_21_2","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1001\/jamainternmed.2019.0600","article-title":"Evaluating a new international risk-prediction tool in IgA nephropathy","volume":"179","author":"Barbour SJ","year":"2019","unstructured":"Barbour SJ, Coppo R, Zhang H Evaluating a new international risk-prediction tool in IgA nephropathy. JAMA Intern. Med. 179(7), 942\u2013952 (2019).","journal-title":"JAMA Intern. Med."},{"issue":"4","key":"e_1_3_10_22_2","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1093\/ndt\/gfx189","article-title":"Glomerular disease frequencies by race, sex and region: results from the International Kidney Biopsy Survey","volume":"33","author":"O'Shaughnessy MM","year":"2018","unstructured":"O'Shaughnessy MM, Hogan SL, Thompson BD Glomerular disease frequencies by race, sex and region: results from the International Kidney Biopsy Survey. Nephrol. Dial. Transplant. 33(4), 661\u2013669 (2018).","journal-title":"Nephrol. Dial. Transplant."},{"issue":"5","key":"e_1_3_10_23_2","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/j.ekir.2023.02.1086","article-title":"IgA nephropathy patient baseline characteristics in the sparsentan PROTECT study","volume":"8","author":"Barratt J","year":"2023","unstructured":"Barratt J, Rovin B, Wong MG IgA nephropathy patient baseline characteristics in the sparsentan PROTECT study. Kidney Int. Rep. 8(5), 1043\u20131056 (2023).","journal-title":"Kidney Int. Rep."},{"issue":"10388","key":"e_1_3_10_24_2","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1016\/S0140-6736(23)00569-X","article-title":"Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial","volume":"401","author":"Heerspink HJL","year":"2023","unstructured":"Heerspink HJL, Radhakrishnan J, Alpers CE Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial. Lancet 401(10388), 1584\u20131594 (2023).","journal-title":"Lancet"},{"key":"e_1_3_10_25_2","doi-asserted-by":"crossref","first-page":"i395","DOI":"10.1093\/ndt\/gfad063c_4499","article-title":"#4499 Matching-adjusted indirect comparison of sparsentan vs delayed-release formulation budesonide for proteinuria reduction in adults with IgA nephropathy","volume":"38","author":"Chai X","year":"2023","unstructured":"Chai X, Bensink M, Gao S #4499 Matching-adjusted indirect comparison of sparsentan vs delayed-release formulation budesonide for proteinuria reduction in adults with IgA nephropathy. Nephrol. Dial. Transplant. 38, i395 (2023).","journal-title":"Nephrol. Dial. Transplant."},{"key":"e_1_3_10_26_2","volume-title":"60th European Renal Association Congress","author":"Bensink M","year":"2023","unstructured":"Bensink M, Gong W, Chai X Matching-adjusted indirect comparison of sparsentan vs. delayed-release formulation budesonide for proteinuria reduction in adults with IgA nephropathy. Presented at: 60th European Renal Association Congress. Milan, Italy (15\u201318 June 2023). (Accessed: 19 September 2025). https:\/\/medicalaffairs.travere.com\/wp-content\/uploads\/2023\/10\/2023_ERA_Bensink_MAIC-Spar-v-Budesodine_Focused-Oral-pdf.pdf"},{"key":"e_1_3_10_27_2","doi-asserted-by":"publisher","DOI":"10.1002\/jrsm.1709"},{"issue":"2","key":"e_1_3_10_28_2","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1177\/0272989X17725740","article-title":"Methods for population-adjusted indirect comparisons in health technology appraisal","volume":"38","author":"Phillippo DM","year":"2018","unstructured":"Phillippo DM, Ades AE, Dias S Methods for population-adjusted indirect comparisons in health technology appraisal. Med. Decis. Making 38(2), 200\u2013211 (2018).","journal-title":"Med. Decis. Making"},{"issue":"1","key":"e_1_3_10_29_2","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1002\/jrsm.1167","article-title":"Automated generation of node-splitting models for assessment of inconsistency in network meta-analysis","volume":"7","author":"van Valkenhoef G","year":"2016","unstructured":"van Valkenhoef G, Dias S, Ades AE, Welton NJ. Automated generation of node-splitting models for assessment of inconsistency in network meta-analysis. Res. Synth. Methods 7(1), 80\u201393 (2016).","journal-title":"Res. Synth. Methods"},{"issue":"4","key":"e_1_3_10_30_2","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/jrsm.1054","article-title":"Automating network meta-analysis","volume":"3","author":"van Valkenhoef G","year":"2012","unstructured":"van Valkenhoef G, Luzqz G, de Brock B Automating network meta-analysis. Res. Synth. Methods 3(4), 285\u2013299 (2012).","journal-title":"Res. Synth. Methods"},{"key":"e_1_3_10_31_2","unstructured":"van Valkenhoef G Kuiper J. GeMTC: network meta-analysis using bayesian methods version 1.0\u20132. (Accessed: 19 September 2025). https:\/\/cran.r-project.org\/web\/packages\/gemtc\/index.html"},{"key":"e_1_3_10_32_2","unstructured":"van Valkenhoef G Bujkiewicz S Efthimiou O GeMTC Manual. (Accessed: 19 September 2025). https:\/\/gemtc.drugis.org\/manual.html"},{"key":"e_1_3_10_33_2","unstructured":"The R Project. The R project for statistical computing. (Accessed: 19 September 2025). https:\/\/www.r-project.org\/"},{"key":"e_1_3_10_34_2","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/2046-4053-1-41","article-title":"Sample size and power considerations in network meta-analysis","volume":"1","author":"Thorlund K","year":"2012","unstructured":"Thorlund K, Mills EJ. Sample size and power considerations in network meta-analysis. Syst. Rev. 1, 41 (2012).","journal-title":"Syst. Rev."},{"key":"e_1_3_10_35_2","first-page":"i744","article-title":"PROTECT and NefIgArd two-year proteinuria and eGFR outcomes in adults with IgA nephropathy: matching-adjusted indirect comparison","volume":"39","author":"Gong W","year":"2024","unstructured":"Gong W, Diva U, Bensink M PROTECT and NefIgArd two-year proteinuria and eGFR outcomes in adults with IgA nephropathy: matching-adjusted indirect comparison. Nephrol. Dial. Transplant. 39, i744\u2013i1745 (2024).","journal-title":"Nephrol. Dial. Transplant."},{"issue":"12","key":"e_1_3_10_36_2","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1681\/ASN.0000000000000244","article-title":"Validity and utility of a hierarchical composite end point for clinical trials of kidney disease progression: a review","volume":"34","author":"Little DJ","year":"2023","unstructured":"Little DJ, Gasparyan SB, Schloemer P Validity and utility of a hierarchical composite end point for clinical trials of kidney disease progression: a review. J. Am. Soc. Nephrol. 34(12), 1928\u20131935 (2023).","journal-title":"J. Am. Soc. Nephrol."},{"issue":"4","key":"e_1_3_10_37_2","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.kint.2025.04.004","article-title":"KDIGO 2025 clinical practice guideline for the management of immunoglobulin A nephropathy (IgAN) and immunoglobulin A vasculitis (IgAV)","volume":"108","author":"Kidney Disease: Improving Global Outcomes (KDIGO) IgAN and IgAV Work Group","year":"2025","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) IgAN and IgAV Work Group. KDIGO 2025 clinical practice guideline for the management of immunoglobulin A nephropathy (IgAN) and immunoglobulin A vasculitis (IgAV). Kidney Int. 108(Suppl. 4), S1\u2013S71 (2025).","journal-title":"Kidney Int."},{"key":"e_1_3_10_38_2","unstructured":"Novartis Pharmaceuticals. Novartis receives FDA accelerated approval for Fabhalta\u00ae (iptacopan) the first and only complement inhibitor for the reduction of proteinuria in primary IgA nephropathy (IgAN). (Accessed: 19 September 2025). https:\/\/www.novartis.com\/news\/media-releases\/novartis-receives-fda-accelerated-approval-fabhalta-iptacopan-first-and-only-complement-inhibitor-reduction-proteinuria-primary-iga-nephropathy-igan"},{"key":"e_1_3_10_39_2","unstructured":"Novartis Pharmaceuticals. Fabhalta\u00ae (iptacopan) US Food and Drug Administration. US Prescribing Information. (2025). https:\/\/www.novartis.com\/us-en\/sites\/novartis_us\/files\/fabhalta.pdf"},{"key":"e_1_3_10_40_2","unstructured":"Novartis Pharmaceuticals. Novartis receives FDA accelerated approval for Vanrafia\u00ae (atrasentan) the first and only selective endothelin A receptor antagonist for proteinuria reduction in primary IgA nephropathy (IgAN). (Accessed: 19 September 2025). https:\/\/www.novartis.com\/news\/media-releases\/novartis-receives-fda-accelerated-approval-vanrafia-atrasentan-first-and-only-selective-endothelin-receptor-antagonist-proteinuria-reduction-primary-iga-nephropathy-igan"},{"key":"e_1_3_10_41_2","unstructured":"Novartis Pharmaceuticals. Vanrafia\u00ae (atrasentan) US Food and Drug Administration. US Prescribing Information. (2025). https:\/\/www.novartis.com\/us-en\/sites\/novartis_us\/files\/vanrafia.pdf"}],"container-title":["Journal of Comparative Effectiveness Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/becarispublishing.com\/doi\/pdf\/10.57264\/cer-2025-0045","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T11:18:07Z","timestamp":1764760687000},"score":1,"resource":{"primary":{"URL":"https:\/\/becarispublishing.com\/doi\/10.57264\/cer-2025-0045"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":39,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["10.57264\/cer-2025-0045"],"URL":"https:\/\/doi.org\/10.57264\/cer-2025-0045","relation":{},"ISSN":["2042-6305","2042-6313"],"issn-type":[{"type":"print","value":"2042-6305"},{"type":"electronic","value":"2042-6313"}],"subject":[],"published":{"date-parts":[[2025,12]]},"article-number":"e250045"}}